Immune Evasion in Cancer: Mechanisms and Therapeutic Approaches

Researchers at Central South University have published a comprehensive review on the mechanisms of immune evasion in cancer and potential therapeutic approaches. The review highlights the complex processes by which tumors evade immune surveillance, including tumor-induced immune suppression, immune checkpoint regulation, and genetic and epigenetic influences. The study also emphasizes the importance of personalized approaches and the integration of multi-omics data to combat therapeutic resistance.

Key Takeaways:

• Immune evasion represents a significant challenge in oncology, allowing tumors to evade immune surveillance and destruction.
• Tumors employ various strategies to escape immune detection, including tumor-induced immune suppression, immune checkpoint regulation, and genetic and epigenetic influences.
• The tumor microenvironment (TME) plays a critical role in fostering immune resistance, and metabolic reprogramming contributes to immune suppression.
• Tumor heterogeneity influences immune evasion, and current immunotherapies have limitations.
• Novel therapeutic strategies, such as bispecific antibodies, oncolytic viruses, and nanotechnology-driven immunotherapies, hold promise for combating cancer.

Statistics:

• Over 50% of cancer patients develop therapeutic resistance to immunotherapies.
• Tumor-induced immune suppression affects up to 70% of cancer patients.
• Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, have shown efficacy in up to 30% of cancer patients.
• The tumor microenvironment plays a role in up to 90% of cancer patients.

Sources:

• Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduction and Targeted Therapy, 2025;10(1):227.
• Central South University, Department of Oral and Maxillofacial Surgery, Center for Stomatology, Xiangya Hospital, Changsha, People's Republic of China.
• Can-Hua Jiang, Muhammad Tufail, and Ning Li are the authors of the reviewed article.